Drug intelligence / Profile preview

Stapholyse

Development stage: Preclinical
Lead developer: ZymIQ Biopharma
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

Stapholyse is an engineered bacteriolytic enzyme developed by ZymIQ Biopharma for the treatment of antimicrobial-resistant (AMR) *Staphylococcus* infections, including Methicillin-resistant *Staphylococcus aureus* (MRSA). As an engineered enzyme-based therapeutic, it is designed to target and rapidly lyse the bacterial cell wall of *Staphylococcus* species, offering a potential alternative or adjunct to traditional antibiotics. The drug is being developed for both human and veterinary applications and is currently in the preclinical stage of development.

Beyond the preview

Go deeper on Stapholyse.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stapholyse.

Explore the full profile